ReviewOncogene2004
Src-family kinases in B-cell development and signaling.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 150 citations in OpenAlex.
- Targeting erythroid cell-derived asparagine inhibits alloimmunization in sickle cell disease.Blood advances · 2026Article
- Integrative analysis of Poly(A)-seq and RNA-seq reveals transcriptional regulation of poly(A) tail length in tuberculosis.Microbiology spectrum · 2026Article
- Functional phenotyping of genomic variants using joint multiomic single-cell DNA-RNA sequencing.Nature methods · 2025Article
- Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition.Pharmaceutics · 2025Review
- Article
- Finnish-specific AKT2 gene variant leads to impaired insulin signalling in myotubes.Journal of molecular endocrinology · 2023Article
- Impact of senolytic treatment on immunity, aging, and disease.Frontiers in aging · 2023Review
- FCRL1 immunoregulation in B cell development and malignancy.Frontiers in immunology · 2023Review
- Review
- MYD88Therapeutic advances in hematology · 2022Review
- Signal Integration by Translocation and Phosphorylation of PKCδ in the B Cell Alternate Pathway.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Review
- How the Discovery of the CD4/CD8-p56Frontiers in cell and developmental biology · 2021Review
- Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.Cancers · 2020Review
- Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy.Kidney diseases (Basel, Switzerland) · 2020Article
- Loci Associated With Antibody Response in Feral Swine (Frontiers in veterinary science · 2020Article
- Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.mBio · 2019Article
- Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques.Molecular cell · 2019Article
- Review
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Src-family protein tyrosine kinases (SFKs) are known to play key roles in initiating signal transduction by the B-cell antigen receptor (BCR). In addition, numerous studies have shown that this family of molecules also contributes to signaling by BCR surrogates during B-lymphocyte lineage development and maturation. Paradoxically, ablation of SFKs not only results in obvious defects in B-cell development but also in the onset of autoimmunity. Thus SFKs, most notably Lyn, play both activating and inhibitory roles in B-cell function. Confounding analyses of SFK function in B cells is the varied coexpression of family members that mediate redundant as well as unique functions. In this review, we will focus mainly on the role of Lyn in mediating positive and negative roles in B-cell activation and how these affect immune signaling and disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.